INTRODUCTION {#s1}
============

DNA replication fidelity in humans is preserved via two distinct repair mechanisms: polymerase proofreading and the mismatch repair (MMR) system ([@MCS004499LINC37]). Proofreading of newly synthesized DNA strands during replication is performed by the 3′--5′ exonuclease activity of the Pol δ and Pol ε replicative polymerase catalytic subunits, POLD1 and POLE, respectively ([@MCS004499LINC20]; [@MCS004499LINC37]). The MMR pathway is a postreplicative error correction mechanism for mismatches evading polymerase proofreading and is primarily effected by MLH1, MSH2, MSH6, and PMS2 ([@MCS004499LINC21]).

Although a functional deficiency in either pathway leads to a "mutator" cellular phenotype ([@MCS004499LINC30]), the association between defective replication repair and cancer is better recognized for the MMR pathway, which is defective in two inherited cancer predisposition syndromes. Monoallelic heterozygous loss-of-function germline mutations in MMR genes cause Lynch syndrome, an autosomal dominant disorder ([@MCS004499LINC31]). In contrast, biallelic (compound heterozygous or homozygous) loss-of-function germline mutations in MMR genes result in constitutional MMR deficiency syndrome (CMMRD), which is inherited in an autosomal recessive pattern ([@MCS004499LINC3]; [@MCS004499LINC50]).

Despite a shared pathogenesis, Lynch syndrome and CMMRD are distinct in inheritance pattern, epidemiology, and clinical features ([@MCS004499LINC1]). CMMRD is characterized by a higher frequency of brain and hematological malignancies and a markedly earlier age of onset (median age at first tumor is \<10 yr) of cancer ([@MCS004499LINC46]). In addition, there are nonmalignant dermatological manifestations including pigmented skin papules and café au lait macules reminiscent of neurofibromatosis type 1 as well as multiple pilomatricomas. These clinical features have been proposed as a scoring system for further diagnostic workup that includes tumor/normal MMR staining by immunohistochemistry and/or microsatellite instability (MSI) evaluation followed by genetic analysis ([@MCS004499LINC3]; [@MCS004499LINC50]; [@MCS004499LINC46]). Tumors in CMMRD patients are invariably "hypermutated" (defined as \>10 mutations/Mb) and often "ultra-hypermutated" (\>100 mutations/Mb) with acquisition of secondary somatic *POLE/POLD1* mutations ([@MCS004499LINC43]; [@MCS004499LINC8]), and characteristic mutational signatures of MMR deficiency may be detected in the tumor genome ([@MCS004499LINC2]).

Recently, a highly penetrant dominant cancer predisposition syndrome was described in kindreds with colonic polyposis and/or carcinomas in germline carriers of *POLE/POLD1* exonuclease domain mutations (EDMs) ([@MCS004499LINC10]; [@MCS004499LINC35]). Initially termed polymerase proofreading-associated polyposis, emerging reports of extracolonic malignancies, including central nervous system (CNS) gliomas as well as pancreatic and endometrial adenocarcinomas ([@MCS004499LINC40]; [@MCS004499LINC23]; [@MCS004499LINC44]; [@MCS004499LINC4]) suggests that the *POLE/POLD1* cancer predisposition syndrome is an evolving entity. *POLE/POLD1* syndrome patients typically receive their first cancer diagnosis in adulthood (median 40 and 32.5 yr for *POLE* and *POLD1*, respectively), which is more similar to Lynch syndrome than CMMRD ([@MCS004499LINC4]). Tumors with *POLE*/*POLD1* EDMs ([@MCS004499LINC13]; [@MCS004499LINC14]) are typically MMR-proficient and microsatellite stable (MSS) and are ultra-hypermutated with a characteristic genomic mutational signature ([@MCS004499LINC2]; [@MCS004499LINC37]; [@MCS004499LINC12]). Recurrent somatic polymerase EDMs are more commonly reported in *POLE* than *POLD1*, with certain hotspot codons (D275, P286, S297, V411, P436, A456, Y458, S459, and S461) associated with very high mutation burdens ([@MCS004499LINC12]). Germline EDMs in familial cases, however, are highly restricted to only a handful of recurrent missense changes including POLE L242V and in certain *POLD1* codons (S478, L474, D316, and R409) ([@MCS004499LINC4]).

In this report, we present a 5-yr-old child with medulloblastoma and clinical features of CMMRD, whose ultra-hypermutated tumor was found to retain MMR expression and harbor a mutation signature of germline *POLE* deficiency. Genetic workup revealed an absence of germline MMR mutations and the discovery of a heterozygous germline *POLE* p.A456P mutation.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The patient is a Latina female who presented at 5 yr of age with a several week progressive history of headache, nausea, vomiting, impaired balance, and frequent falling toward her right side. Initial physical examination revealed more than 100 hyperpigmented macules and papules over her entire body, including some with classic café au lait macule features ([Fig. 1](#MCS004499LINF1){ref-type="fig"}A,B). Maternal family history was negative for relatives with any early-onset cancers, and both maternal half-siblings are healthy without chronic medical conditions or hyperpigmented skin lesions. Paternal family and medical history were unavailable.

![Representative images of numerous hyperpigmented skin lesions on the head (*A*) and back (*B*). Representative sagittal (*C*) and axial (*D*) MRI images showing a posterior fossa mass. Representative low-power (*E*) and high-power (*F*) images of the anaplastic medulloblastoma specimen demonstrating small round cells, mitotic figures, and scattered multinucleated giant cells. Immunohistochemistry for MMR proteins (*G*--*J*) revealing retained expression of MLH1, MSH2, MSH6, and PMS2, respectively.](MCS004499Lin_F1){#MCS004499LINF1}

A head CT revealed a posterior fossa mass and obstructive hydrocephalus. Subsequent MRI confirmed the presence of a left cerebellar heterogeneously enhancing tumor with restricted diffusion, in addition to multifocal leptomeningeal metastatic disease along the cerebellum ([Fig. 1](#MCS004499LINF1){ref-type="fig"}C,D). The patient was additionally noted to have left-sided complex renal cyst, a right distal tibia osteochondroma, and three superficial hard palpable subcutaneous calcified nodules on her extremities, which were subsequently diagnosed as pilomatricomas on pathology examination.

A gross total resection of the primary posterior fossa tumor was performed. Pathologic examination revealed a large cell anaplastic medulloblastoma with several atypical mitotic figures, apoptosis, regional necrosis, and giant multinucleated cells ([Fig. 1](#MCS004499LINF1){ref-type="fig"}E,F). Additional medulloblastoma subclassification using fluorescence in situ hybridization probes for Chromosome 6q23 (monosomy 6), *MYC*, *MYCN*, *EGFR*, *PTEN* (monosomy 10), and immunohistochemistry (GLI1, YAP1, β-catenin, p53, FOXG1) revealed a non-WNT/non-SHH medulloblastoma without *MYC*/*MYCN* amplification. MMR immunohistochemistry of the tumor revealed staining for all four MMR proteins to be strongly retained in both tumor and normal cells ([Fig. 1](#MCS004499LINF1){ref-type="fig"}G--J).

Genomic Analyses {#s2b}
----------------

Given the suspected diagnosis of CMMRD, genetic analysis was performed on both germline and tumor specimens. Germline analysis of MMR pathway genes (*MLH1, MSH2, MSH6*, and *PMS2*) and other genes associated with childhood brain tumors (*TP53*, *PTCH1*, *NF1*, *APC*, etc.) ([Table 1](#MCS004499LINTB1){ref-type="table"}) using gene panels featuring variant and deletion/duplication analysis (including for *EPCAM*) was negative for any pathogenic or likely pathogenic variants or copy-number abnormalities.

###### 

Panel genes tested for pathogenic germline variants in the patient

  Panel                                                                   Genes
  ----------------------------------------------------------------------- -------------------------------------------------------------------------------
  Hereditary high-risk CRC panel                                          *APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53*
  Hereditary brain/CNS/PNS cancer panel (unique genes not on CRC panel)   *ALK, ATM, MEN1, MRE11A, NBN, NF2, PALB2, PHOX2B, PTCH1, SUFU, VHL*

(CRC) Colorectal cancer, (CNS) central nervous system, (PNS) peripheral nervous system.

Tumor variant analysis was undertaken on the medulloblastoma specimen using a 124-gene next-generation sequencing (NGS) panel in a CLIA-certified laboratory ([Supplemental Table S1A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004499/-/DC1)) revealing several loss-of-function variants in genes commonly mutated in medulloblastoma ([Table 2](#MCS004499LINTB2){ref-type="table"}), including pathogenic nonsense mutations in *TP53* and *APC* that, as noted above, were absent in the germline of the patient in testing for familial cancer predisposition ([Table 1](#MCS004499LINTB1){ref-type="table"}), confirming a somatic origin for these mutations. The key finding, however, was that of an ultra-hypermutated tumor with a markedly increased tumor mutation burden (TMB) estimated at \>150 mutations/Mb of the genome. Notably, 72/94 variants on the tumor panel report had no entries in reference population databases with at least 25% (18/72) being nonsense mutations.

###### 

Relevant tumor panel findings

  Gene      hg19 position      CDS change     AA change      Variant type   Origin    dbSNP         Variant allele fraction   COSMIC ID
  --------- ------------------ -------------- -------------- -------------- --------- ------------- ------------------------- -----------
  *APC*     Chr 5:112175124    c.3833C\>A     p.Ser1278Ter   Nonsense       Somatic                 27.40%                    COSM19313
  *KDM6A*   Chr X:44950066     c.3835C\>T     p.Arg1279Ter   Nonsense       Somatic   rs863224886   50.00%                    COSM28780
  *NF2*     Chr 22:30070832    c.1348G\>T     p.Glu450Ter    Nonsense       Somatic                 49.60%                    
  *PTCH1*   Chr 9:98244436     c.634G\>T      p.Glu212Ter    Nonsense       Somatic                 43.70%                    
  *SUFU*    Chr 10:104387001   c.1365+1G\>T                  Splicing       Somatic                 46.30%                    
  *TP53*    Chr 17:7578212     c.637C\>T      p.Arg213Ter    Nonsense       Somatic   rs397516436   98.80%                    COSM10654

(CDS) Coding sequence, (AA) amino acid.

Given the profile of an MMR-proficient ultra-hypermutated tumor, the possibility of a polymerase proofreading error-related mechanism was entertained. Mutation signature analysis of all tumor point mutations and the surrounding trinucleotide context revealed a disproportionate frequency of C\>A transversions (∼35%) and C\>T transitions (∼50%), with the T\[C\>T\]G (24%) and T\[C\>A\]T (18%) signature together comprising \>40% of the mutational burden ([Fig. 2](#MCS004499LINF2){ref-type="fig"}A). This mutational pattern is characteristic of COSMIC "signature 10" ([@MCS004499LINC2]; [@MCS004499LINC37]) and an unsupervised similarity analysis of the tumor mutational profile to all published signature patterns confirmed the highest cosine similarity of 0.87 (1 being identical) to that signature ([Fig. 2](#MCS004499LINF2){ref-type="fig"}B).

![Mutation signature analysis and identification of germline *POLE* mutation. Mutation signature profile of the tumor as represented on the 96-substitution classification (*A*) along with the trinucleotide context. Mutations and the contexts are plotted on the horizontal axis, and the vertical axis represents the proportional contribution of each pattern to the overall signature. A striking pattern of increased C\>A \[TCT\] and C\>T \[TCG\] trinucleotide contexts forming ∼40% of all changes is observed, which has been strongly associated with "signature 10," and confirmed on mutational pattern similarity analysis against all 30 COSMIC signatures (*B*) showing closest match to "signature 10" (cosine similarity 0.87). The signature prediction of germline *POLE* alteration was corroborated by germline and tumor sequencing revealing a *POLE* p.A456P mutation (*C*) in the germline (*top* panel, "G") and tumor (*bottom* panel, "T"). In contrast, a heterozygous *MSH6* nonsense mutation was only seen in the tumor (*D*).](MCS004499Lin_F2){#MCS004499LINF2}

Because of the known association between signature 10 and germline *POLE* deficiency, a 981-gene comprehensive cancer panel ([Supplemental Table S1B](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004499/-/DC1)) containing *POLE/POLD1* and MMR genes was used to sequence genomic DNA from germline and tumor specimens. The analysis revealed a heterozygous germline missense mutation in exon 14 of *POLE*: NM_006231.3(*POLE*):c.1366G\>C (p.Ala456Pro) ([Table 3](#MCS004499LINTB3){ref-type="table"}; [Fig. 2](#MCS004499LINF2){ref-type="fig"}C). This variant, previously reported as a recurrent somatic *POLE* driver mutation and associated with a high mutation burden ([@MCS004499LINC12]), lies within the Exo III motif of the POLE exonuclease domain in close proximity to several recurrent somatic *POLE* mutations. The p.A456P mutation alters a highly conserved alanine residue that is predicted to affect DNA binding and lead to defective proofreading activity ([@MCS004499LINC14]). No additional somatic *POLE* mutation (or copy-number change and/or LOH) as a second hit was noted. Further genetic testing for *POLE* in the mother revealed that she did not harbor the germline p.A456P variant. Repeated attempts by the clinical team to reach the father for familial testing were unsuccessful; thus, a paternally inherited mutation cannot be ruled out.

###### 

Germline *POLE* and somatic *MSH6* variants detected in the patient

  Gene     hg19 position   Depth at position (G, T)   CDS change   AA change   Variant type   Origin   Predicted effect   dbSNP   Geno   ClinVar ID
  -------- --------------- -------------------------- ------------ ----------- -------------- -------- ------------------ ------- ------ ----------------
  *POLE*   12:133249857    51, 136                    c.1366G\>C   p.A456P     Missense       G        Del                --      Het    SCV000825544.1
  *MSH6*   2:48027844      302, 1004                  c.2722G\>T   p.Q908X     Nonsense       S        Del                --      Het    

(CDS) Coding sequence, (AA) amino acid, (G) germline, (S) somatic, (T) tumor, (Del) deleterious, (Het) heterozygous.

The comprehensive cancer panel testing of the tumor also revealed a nonsense mutation in exon 4 of *MSH6* that was not present in the germline: NM_000179.2(*MSH6*):c.2722G\>T (p.Glu908Ter) at 46.7% variant allele fraction ([Fig. 2](#MCS004499LINF2){ref-type="fig"}D). No second hit in *MSH6* or other alterations in the MMR genes were detected, consistent with the retention of MMR staining in the cells ([Fig. 1](#MCS004499LINF1){ref-type="fig"}G--J). Both the germline *POLE* and somatic *MSH6* variants were independently confirmed by direct Sanger sequencing. No other pathogenic alterations in any of the remaining polymerase genes were detected.

Clinical Course {#s2c}
---------------

Following clinical recovery from gross total resection of the primary tumor, the patient was treated with proton beam craniospinal irradiation (at 3600 cobalt Gray equivalent plus boost to tumor bed and nodules) followed by seven cycles of chemotherapy (including vincristine, cisplatin, cyclophosphamide, gemcitabine, and pemetrexed) on a high-risk arm of a multi-institutional phase 2 clinical trial for patients with newly diagnosed medulloblastoma. Her chemotherapy courses were complicated by malnutrition necessitating enteral caloric supplementation via nasogastric tube and recurrent episodes of *Clostridium difficile* colitis and methicillin-susceptible *Staphylococcus aureus* bacteremia. She otherwise tolerated her treatment without severe complication and is doing well without evidence of medulloblastoma recurrence or progression of leptomeningeal metastasis 4 mo after completion of treatment.

Clinical experts in pediatric cancer surveillance were consulted to devise a customized screening protocol including at least annual brain MRI imaging indefinitely given the need for surveillance for recurrence as well as new *POLE* polymerase cancer syndrome--related brain tumors. She additionally will soon be undergoing a baseline colonoscopy. The timing of subsequent serial evaluations will be based on the presence or absence of colon adenomas; if no adenomas are identified, a repeat colonoscopy can be delayed until the patient becomes a teenager. She is followed biannually by dermatology and will undergo annual gynecology exams on reaching adulthood.

DISCUSSION {#s3}
==========

This case illustrates several novel and striking aspects of the still-evolving *POLE/POLD1* polymerase cancer syndrome as well as the utility of integrative tumor sequencing and mutation signature analysis in accurately predicting the underlying mutational mechanism in a tumor.

First, the patient presented with clinical features indistinguishable from that of CMMRD based on current diagnostic criteria proposed by the C4CMMRD consortium ([@MCS004499LINC50]), including a pediatric-onset tumor (1 point), numerous café au lait macules (2 points), and multiple pilomatricomas (2 points), with a score of ≥3 suggested to prompt screening for MMR deficiency (MMR-D). Other investigators have recently reported a 14-yr-old boy with rectosigmoid carcinoma and CMMRD-like dermatological manifestations and a germline *POLE* missense mutation (p.V411L) ([@MCS004499LINC51]), suggesting that the characteristic skin manifestations of CMMRD may be common to different DNA repair defect syndromes. Our results corroborate that and provide further evidence that a *POLE/POLD1* deficiency should be considered in the differential of CMMRD patients, particularly if further testing excludes MMR deficiency.

Second, to our knowledge, at age 5 yr, this is the youngest cancer presentation reported in a patient with germline *POLE/POLD1* cancer predisposition syndrome. Except for the 14-yr-old boy described by [@MCS004499LINC51] with a negative family history, to date, the median age at first cancer diagnosis in all known familial cases of *POLE/POLD1* syndrome is reported to be in the fourth decade (earliest 27 yr) ([@MCS004499LINC4]). The presentation in early childhood is, therefore, highly unusual and contributed to further overlap with the clinical presentation of CMMRD.

Third, this is the first report of the *POLE* p.A456P mutation as a germline alteration. The p.A456P EDM is a known recurrent somatic hotspot mutation that has been previously reported in at least 32 tumors ([Table 4](#MCS004499LINTB4){ref-type="table"}) (COSM937319), including hyper/ultra-hypermutated tumors with mutational signatures characteristic of *POLE* proofreading deficiency ([@MCS004499LINC42]). Review of the literature reveals that the TMB, when reported, is invariably high in all tumors harboring the p.A456P mutation ([Table 4](#MCS004499LINTB4){ref-type="table"}). The alanine at codon 456 is highly conserved from humans to *Drosophila*, and structural analysis predicts mutation of this site to lead to altered DNA binding through distortion of the polymerase active site ([@MCS004499LINC14]). Taken together, the p.A456P EDM is considered a driver *POLE* mutation in human carcinogenesis ([@MCS004499LINC12]) and is the most likely cause of the phenotype in this patient. As important, the mutation was found to be absent in the germline of the asymptomatic mother, although paternal inheritance could not be ruled out.

###### 

Reported POLE p.A456P tumor mutations and associated mutation burden

  Tumor                              Total cases   TMB-ultra   TMB-hyper   TMB-low   TMB-ND   Reference(s)
  ---------------------------------- ------------- ----------- ----------- --------- -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Colorectal carcinoma               7             5           1           \-        1        [@MCS004499LINC42]; [@MCS004499LINC45]; [@MCS004499LINC25]; [@MCS004499LINC12]
  Endometrial carcinoma              21            2           2           \-        17       [@MCS004499LINC14]; [@MCS004499LINC27]; [@MCS004499LINC6]; [@MCS004499LINC47]; [@MCS004499LINC17]; [@MCS004499LINC32]; [@MCS004499LINC5]; [@MCS004499LINC12]; [@MCS004499LINC18]; [@MCS004499LINC48]
  Glioblastoma multiforme            1             1           \-          \-        \-       [@MCS004499LINC24]
  Ovarian carcinoma                  2             \-          1           \-        1        [@MCS004499LINC12]; [@MCS004499LINC36]
  Cervical squamous cell carcinoma   1             \-          1           \-        \-       [@MCS004499LINC12]

(TMB) Tumor mutation burden, (hyper) hypermutated (\>10/Mb), (ultra) ultra-hypermutated (\>100/Mb), (ND) not determined.

The combination of an unusually early age of onset with a novel germline occurrence of a recurrent somatic mutation raises the possibility of the p.A456P EDM leading to a more severe *POLE* proofreading defect. It is noteworthy that in a large screen of cancers for driver *POLE* EDMs ([@MCS004499LINC12]), both the p.A456P mutation and the p.V411L mutation reported previously in the 14-yr-old boy ([@MCS004499LINC51]) were characterized as strong "mutators" because of a tight correlation with elevated TMB. In contrast, using functional assays and association with TMB, the only recurrent familial germline *POLE* mutation (p.L424V) was found to have a weak "mutator" phenotype ([@MCS004499LINC42]; [@MCS004499LINC12]), possibly correlating with a later age of onset seen in those individuals. Further reports of other *POLE* EDMs in the germline along with functional studies would be necessary to clarify the genotype--phenotype correlation between the severity of the *POLE* mutation and age of onset.

Ultra-hypermutation was first recognized in adult-onset MSS colon cancers that were found to be enriched for *POLE* and, less commonly, *POLD1* EDMs ([@MCS004499LINC13]; [@MCS004499LINC15]; [@MCS004499LINC35]). Childhood cancer genomes are typically characterized by a low TMB ([@MCS004499LINC49]; [@MCS004499LINC41]) with hyper/ultra-hypermutation seen in \<1% of all pediatric cancers, primarily in the context of CMMRD ([@MCS004499LINC22]). Tumor profiling using NGS panels to direct management of cancers is now common in clinical practice, and this report highlights the utility of tumor sequencing and analysis. Detection of an ultra-hypermutated tumor has potentially major therapeutic implications for this patient as a positive association between TMB and the response to therapeutic immune checkpoint inhibition, including improved progression-free survival and increased rates of objective response, presumed secondary to an increased number of neoantigens in hypermutated tumors ([@MCS004499LINC39]; [@MCS004499LINC9]; [@MCS004499LINC28]; [@MCS004499LINC34]), is now well-established. In the event of tumor recurrence in this patient, treatment with a PD-1 or PD-L1 inhibitor will be strongly considered. Multiple clinical trials of immune checkpoint inhibitors specifically enrolling patients with hypermutated tumors are currently available (Clinical Trials NCT02359565, NCT02992964).

In addition, the identification of ultra-hypermutation on tumor panel analysis in the absence of MMR-D (as evidenced by negative MMR genetic testing and retained MMR expression by IHC) for the first time raised the possibility of a germline *POLE* deficiency as the primary genetic defect, despite the unusually young age at presentation for that diagnosis. The tumor mutational signature analysis revealed an unambiguous "signature 10" pattern that is a "canonical" signature of POLE deficiency ([@MCS004499LINC2]; [@MCS004499LINC12]). This directed further evaluation of the tumor and germline specimens for *POLE/POLD1* mutations revealing the deleterious *POLE* p.A456P mutation in the germline. This report corroborates the accuracy of mutational signature analysis of hypermutated tumors from tumor panel sequencing data in prospectively predicting the underlying genetic defect, as proposed recently in the form of a diagnostic algorithm for hypermutated childhood tumors ([@MCS004499LINC12]). The correlations reported here and elsewhere ([@MCS004499LINC12]) emphasize that germline testing for CMMRD and *POLE/POLD1* inherited cancer syndrome may result from either clinical features or tumor mutation spectrum (when available). Notably, identification of the germline *POLE* defect in our patient along with the reported pediatric CRC case ([@MCS004499LINC51]) has also led to modification in the follow-up care, as current cancer screening recommendations for patients with germline *POLE* mutations include colonoscopies every 1--2 yr and gastroduodenoscopies every 3 yr beginning at 18--25 yr old ([@MCS004499LINC44]; [@MCS004499LINC4]; [@MCS004499LINC37]; [@MCS004499LINC11]).

Finally, although both colonic and extracolonic malignancies, including CNS astrocytomas, have been previously reported in familial *POLE/POLD1* mutation carriers, ([@MCS004499LINC40]; [@MCS004499LINC23]; [@MCS004499LINC44]; [@MCS004499LINC4]; [@MCS004499LINC26]; [@MCS004499LINC19]), to our knowledge, this is the first report of a medulloblastoma as the presenting malignancy in a patient with germline *POLE* mutation. Except for the scattered giant multinucleated cells that have been previously reported in hypermutated glioblastomas with somatic *POLE* mutations ([@MCS004499LINC16]), the histopathological characteristics of the anaplastic medulloblastoma were characteristic. Our report, therefore, extends both the age of diagnosis and the spectrum of tumors seen in *POLE/POLD1* syndrome patients and suggests that the phenotype of this newly described cancer predisposition syndrome is still being defined.

METHODS {#s4}
=======

The study was performed after obtaining informed consent for enrollment on a Baylor College of Medicine Institutional Review Board-approved study.

Genomic DNA was extracted from blood and the medulloblastoma specimen utilizing the QIAamp DNA Mini Kit and the DNA FFPE Tissue Kit (QIAGEN), respectively. Germline DNA underwent clinical sequencing at two CLIA-certified reference laboratories: Baylor Genetics laboratory for the Hereditary High-risk CRC panel and the Hereditary Brain/CNS/PNS panel and at Invitae laboratories for *POLE* testing. Additional sequencing using the SeqCap EZ Human Oncology Panel (Roche Inc.) was performed at Texas Children\'s Hospital. Tumor DNA underwent clinical sequencing at the CLIA-certified Texas Children\'s Hospital laboratory using the Solid Tumor NGS panel as well as the Human Oncology Panel. A list of genes covered on the tumor panels is included in [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004499/-/DC1).

Sequencing by the hereditary cancer panels at Baylor Genetics featured Illumina-based NGS variant analysis and MLPA/CGH-based deletion/duplication analysis of familial cancer genes ([Table 1](#MCS004499LINTB1){ref-type="table"}). For the human oncology panel and solid tumor panels, NGS libraries were generated using 50 ng of DNA and subsequently pooled in either 4-plex or 2-plex for hybridization capture with respective capture probe set. Captured pools were then sequenced on an Illumina MiSeq with 600V3 chemistry (2 × 150-bp read length). Coverage metrics for the sequenced samples are provided in [Table 5](#MCS004499LINTB5){ref-type="table"}. NextGENe (SoftGenetics) and Platypus ([@MCS004499LINC38]) were utilized for variant calling, followed by annotation with VEP ([@MCS004499LINC33]). Mutation prediction algorithms (PolyPhen, SIFT, LRT, MutationTaster) were used using dbNSFP ([@MCS004499LINC29]) to predict the biological effect of the mutation.

###### 

Sequencing metrics on the human oncology panel for the tumor and germline specimens

  Sample     Total reads   Percent aligned reads   Percent reads on target   Average coverage
  ---------- ------------- ----------------------- ------------------------- ------------------
  Germline   7,096,416     94.29%                  68.95%                    181.92
  Tumor      20,774,903    95.49%                  77.56%                    581.33

Mutation signature analysis and visualization were generated using the Mutational Patterns Bioconductor package in R ([@MCS004499LINC7]). The package was utilized to generate the 96-substitution classification profile ([@MCS004499LINC2]) with all substitutions converted to the pyrimidine of the Watson--Crick base pair and representing the immediate trinucleotide context (5′ × 3′) of the mutated base. The optimal nonnegative linear combination of COSMIC signatures was then fitted to the substitution classification profile, followed by calculation of the cosine similarity between the tumor mutation signature in this patient and the COSMIC signatures to determine the mutation signature classes that best fit the signature of the patient.

Tumor mutation burden was calculated from the solid tumor mutation panel (∼1 Mb capture size) using the total number of nonsynonymous variants in the coding region of the panel adjusted for the panel size.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The *POLE* variant can be found in ClinVar (<https://www.ncbi.nnlm.nih.gov/clinvar/>) under accession number SCV000825544.1. The *MSH6* variant was submitted to ClinVar and can be found under accession number SCV000965671.1. Tumor and germline targeted sequencing data from the human oncology panel will be deposited to the National Center for Biotechnology Information (NCBI) Database of Genotypes and Phenotypes (dbGaP; <http://www.ncbi.nlm.nih.gov/gap>).
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